Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) Sees Large Increase in Short Interest

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) was the recipient of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 1,384,700 shares, an increase of 33.5% from the February 13th total of 1,037,100 shares. Based on an average daily volume of 11,200 shares, the days-to-cover ratio is presently 123.6 days.

Telix Pharmaceuticals Trading Up 1.8 %

TLPPF traded up $0.31 during trading on Friday, hitting $17.90. The company’s stock had a trading volume of 1,873 shares, compared to its average volume of 4,877. The firm’s 50 day moving average price is $17.43 and its two-hundred day moving average price is $15.48. Telix Pharmaceuticals has a 12 month low of $7.73 and a 12 month high of $24.85.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma.